Heart septal defects refer to congenital conditions characterized by abnormal openings or holes in the walls (septa) that separate the chambers of the heart. These defects can occur in the atrial septum (atrial septal defect, ASD) or the ventricular septum (ventricular septal defect, VSD). These openings disrupt the normal flow of blood through the heart, leading to potential complications such as increased pressure in the lungs and strain on the heart. The severity of symptoms and the necessary interventions vary, with some cases requiring surgical correction. Early diagnosis and intervention are crucial in managing heart septal defects, enabling healthcare professionals to implement appropriate treatment strategies and provide optimal care for affected individuals. Advances in medical science and technology continue to enhance our understanding of these defects, leading to improved diagnostic techniques and more effective treatment options.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States